97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
#1802MOLECULES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
#1803NEOADJUVANT CANCER TREATMENT
#1804Recombinant plasma membrane-based vesicle, for treating cancer
#1805Methods of Treating Cancer
#1806Fragment size characterization of cell-free DNA mutations from clonal hematopoiesis
#1807Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
#1808B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
#1809Anti-TREM1 antibodies and related methods
#1810ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#1811Methods for treatment of cancer comprising TIGIT-binding agents
#1812Chimeric antibody/T-cell receptor constructs and uses thereof
#1813Splicing modulator antibody-drug conjugates and methods of use
#1814AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB
#1815Enhancing the therapeutic activity of an immune checkpoint inhibitor
#1816Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
#1817BIORESPONSIVE HYDROGEL MATRIXES AND METHODS OF USE
#1818CD8+ t cell based immunosuppressive tumor microenvironment detection method
#1819Dimers and use thereof
#1820Antibody molecules for cancer treatment
#1821ACTIVATION OF RESIDENT MEMORY T CELLS FOR THE TREATMENT OF CANCER
#1822Methods and materials for treating cancer
#1823APPLICATION OF PLANT AS HOST IN EXPRESSING PD-1 ANTIBODY AND/OR PD-L1 ANTIBODY
#1824PD1 AND PDL1 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY
#1825Combination therapies
#1826PD-L1 -binding molecules comprising Shiga toxin A subunit scaffolds
#1827PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
#1828B7-H4 antibodies and methods and use thereof
#1829Anti-PD-L1 antibody for detecting PD-L1
#1830METHODS OF TREATING CANCER WITH DENDRITIC CELL MOBILIZING AGENTS
#1831Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
#1832COMBINATION TUMOR TREATMENT WITH AN INTEGRIN-BINDING-FC FUSION PROTEIN AND IMMUNE STIMULATOR
#1833AXL-SPECIFIC ANTIBODIES FOR CANCER TREATMENT
#1834Methods for treating late-stage small cell lung cancer by administering a human anti-PD-L1 antibody, an etoposide and a platinum-based therapeutic
#1835B7-H4 ANTIBODY DOSING REGIMENS
#1836B7-H4 ANTIBODY FORMULATIONS
#1837FC VARIANT COMPOSITIONS AND METHODS OF USE THEREOF
#1838Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor
#1839PD-L1 ANTAGONIST COMBINATION TREATMENTS
#1840Methods of making novel pharmaceutical compositions
#1841Anticancer combination of chidamide and celecoxib salts
#1842PDL-1 INHIBITORS IN TREATMENT OF PULMONARY VASCULAR DISEASES
#1843DOSING REGIMENS FOR TARGETED TGF-B INHIBITION FOR USE IN TREATING CANCER IN TREATMENT NAÏVE SUBJECTS
#1844Modified N-810 and Methods Therefor
#1845Pharmaceutical composition comprising particles and methods of making same
#1846Agents and methods for predicting response to therapy
#1847Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
#1848Anti-CD25 antibody agents
#1849FORMULATIONS OF HUMAN ANTI-PD-LI ANTIBODIES
#1850Anti-PD-L1 antibody and use thereof
#1851Anti-PD-L1 antibodies and uses thereof
#1852Single-domain antibodies and variants thereof against TIGIT
#1853PD-1/PD-L1 inhibitors
#1854Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
#1855Pharmaceutical Composition for Cancer Treatment
#1856Anti-CD25 for tumour specific cell depletion
#1857TREATMENT OF OVARIAN CANCER WITH ANTI-CD47 AND ANTI-PD-L1
#1858Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
#1859Methods and compositions for decreasing soluble immune receptor CD28
#1860METHODS OF SELECTING AND DESIGNING SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODIES FOR CANCER THERAPY
#1861VIP antagonists and uses in treating cancer
#1862COMBINATION THERAPEUTICS
#1863Anti-CD25 for tumour specific cell depletion
#1864METHODS OF TREATING HER2-POSITIVE CANCER
#1865Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
#1866Multi-Specific Molecules
#1867COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, ENHANCING DRUG POTENCY AND TREATING CANCER, AND METHODS FOR MAKING AND USING SAME
#1868Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
#1869B7-H4 antibodies and methods of use thereof
#1870ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#1871METHODS OF TREATING TUMOR
#1872METHOD FOR EFFICIENTLY ACTIVATING AND EXPANDING T CELLS
#1873ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#1874COMBINED INHIBITION OF SEMAPHORIN-4D AND TGF-BETA AND COMPOSITIONS THEREFOR
#1875VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
#1876HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER
#1877IL-15-based molecules and methods of use thereof
#1878ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
#1879CHIMERIC RECEPTOR
#1880Compositions and methods for tumor immunotherapy
#1881Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
#1882METHODS OF QUALITATIVELY AND/OR QUANTITATIVELY ANALYZING PROPERTIES OF ACTIVATABLE ANTIBODIES AND USES THEREOF
#1883RECOMBINANT THERAPEUTIC INTERVENTIONS FOR CANCER
#1884METHODS FOR PREDICTING AND ENHANCING THERAPEUTIC BENEFIT FROM CHECKPOINT INHIBITORS IN CANCER
#1885BI-FUNCTIONAL PROTEINS AND CONSTRUCTION THEREOF
#1886Guidance and Navigation Control proteins and method of making and using thereof
#1887PD-L1 binding fibronectin type III domains
#1888Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy
#1889Therapeutic agent for cancer
#1890HIGH AFFINITY NEUTRALIZING MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) AND USES THEREOF
#1891Antibodies binding to vista at acidic pH
#1892Targeted binding agents against B7-H1
#1893ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#1894HIV vaccines and methods of making and using
#1895Combination comprising immunostimulatory oligonucleotides
#1896Treating and preventing microbial infections
#1897Methods of using monoclonal antibodies targeting epitopes of ASPH
#1898Anti-CD25 for tumour specific cell depletion
#1899Anti-CD25 for tumour specific cell depletion
#1900Anti-CD25 for tumour specific cell depletion
#1901Anti-CD25 antibody agents
#1902Trispecific antagonists
#1903Anti-PD-L1 antibodies
#1904Compositions and methods for T cell delivery of therapeutic molecules
#1905Nano-vesicles derived from genus cupriavidus bacteria and use thereof
#1906Bicyclic compounds and their use in the treatment of cancer
#1907BIOMARKER FOR PREDICTING EFFECTS OF ANTI-PD-1 ANTIBODY/ANTI-PD-L1 ANTIBODY THERAPY
#1908COMPOSITIONS AND METHODS FOR TREATING CANCER
#1909COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
#1910PD-L1 NANOBODIES, PREPARATION METHODS AND USES THEREOF
#1911Antagonists targeting the TGF-β pathway
#1912Inhibitors of glucocorticoid receptor
#1913Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#1914COMBINATION THERAPIES
#1915ENGINEERED NANOVESICLES AS CHECKPOINT BLOCKADE FOR CANCER IMMUNOTHERAPY
#1916CD137 antibodies for T-cell activation
#1917Anti-CD25 antibody agents
#1918USE OF A CEA CD3 BISPECIFIC ANTIBODY AND A PD-1 AXIS BINDING ANTAGONIST IN A DOSAGE REGIMEN TO TREAT CANCER
#1919Anti-VISTA antibody and use thereof
#1920PD-1 and PD-L1 binding agents
#1921Antagonistic PD-1, PD-L1 and LAG-3 binding proteins
#1922Bispecific antibody for ICOS and PD-L1
#1923POSITRON EMISSION TOMOGRAPHY IMAGING OF ACTIVATABLE BINDING POLYPEPTIDES AND RELATED COMPOSITIONS THEREOF
#1924METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
#1925IRF-4 engineered T cells and uses thereof in treating cancer
#1926CANCER TREATMENT USING COMBINATION OF NEUTROPHIL MODULATOR WITH MODULATOR OF IMMUNE CHECKPOINT
#1927PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS
#1928DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES
#1929PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
#1930METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#1931TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY
#1932IMMUNOMODULATING TREATMENTS OF BODY CAVITIES
#1933METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#1934Antibodies to human B7x for treatment of metastatic cancer
#1935Combination therapy with targeted OX40 agonists
#1936Methods for treating colon cancer or inhibiting cell proliferation by administering a combination of antibodies against human CSF-1R and antibodies against human PD-L1
#1937AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF
#1938COMPOSITIONS, ARTICLES OF MANUFACTURE AND METHODS FOR TREATING CANCER
#1939MONOCLONAL ANTIBODIES AGAINST HUMAN PD-L1 AND USES THEREOF
#1940HUMAN MONOCLONAL ANTI-PD-L1 ANTIBODIES AND METHODS OF USE
#1941COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
#1942Anti-C10orf54 antibodies and uses thereof
#1943Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof
#1944Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#1945Stable Dual Variable Domain Immunoglobulin Protein Formulations
#1946Method for producing antibody-drug conjugate
#1947Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
#1948Methods for treating hematologic cancers
#1949COMPOSITIONS AND METHODS FOR TREATING CANCER
#1950MULTISPECIFIC MOLECULES AND USES THEREOF
#1951METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
#1952Anti-CD277 antibodies
#1953COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS
#1954Methods for characterizing bladder cancer
#1955Immunostimulatory agonistic antibodies for use in treating cancer
#1956Anti-human PD-L2 antibodies
#1957Monoclonal antibody to PD-L1
#1958BSL2v2c2-Ig POLYPEPTIDES
#1959COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
#1960Compositions and methods for cell targeting therapies
#1961PD-1/PD-L1 INHIBITORS FOR THE TREATMENT OF CANCER
#1962Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
#1963Substituted halo-quinoline derivatives, method of preparation and applications thereof
#1964Compositions and Methods for Treating Cancer with Arginine Depletion and Immuno Oncology Agents
#1965Bifunctional fusion protein targeting CD47 and PD-L1
#1966SINGLE-CHAIN MULTIVALENT BINDING PROTEINS WITH EFFECTOR FUNCTION
#1967XCR1 BINDING AGENTS AND USES THEREOF
#1968Methods And Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy
#1969Anti-CD73 anti-PD-L1 bispecific antibodies
#1970BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF
#1971RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
#1972Method of treating glioblastoma multiforme
#1973PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
#1974PROTEINACEOUS MOLECULES AND USES THEREFOR
#1975Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
#1976ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#1977Reducing beta-catenin and IDO expression to potentiate immunotherapy
#1978BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#1979Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
#1980Humanized anti-PD-L1 antibodies
#1981Anti-PD-L1 antibody and uses thereof
#1982Neutralization of inhibitory pathways in lymphocytes
#1983Methods for modulating an immune response
#1984HUMAN ANTIBODIES TO PD-1
#1985USES OF PD-1/PD-L1 INHIBITORS AND/OR CTLA-4 INHIBITORS WITH A BIOLOGIC CONTAINING MULTIPLE CYTOKINE COMPONENTS TO TREAT CANCER
#1986Therapeutic compositions, combinations, and methods of use
#1987Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
#1988IMMUNE-BASED TREATMENT OF KRAS-VARIANT CANCER PATIENTS
#1989Peptides for molecular detection of PD-L1
#1990Binding molecules that modulate a biological activity expressed by a cell
#1991VEGFR-antibody light chain fusion protein
#1992Methods for modulating an immune response
#1993COMBINATION THERAPIES COMPRISING DENDRITIC CELLS-BASED VACCINE AND IMMUNE CHECKPOINT INHIBITOR
#1994ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY FOR TREATING TUMORS
#1995ANTI-PD-L1 ANTIBODIES AND USES THEREOF
#1996SEMAPHORIN-4D ANTAGONISTS FOR USE IN CANCER THERAPY
#1997Fusion protein dimer using antibody Fc region as backbone and use thereof
#1998Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#1999Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
#2000Therapeutic heterocyclic compounds
#2001Anti-LY6H antibodies and antibody drug conjugates
#2002Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein
#2003CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
#2004Therapeutic interferon alpha 1 proteins
#2005Immunocytokines for the treatment of cancer
#2006Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
#2007Bispecific cytotoxic lymphocyte or macrophage-redirecting autoantibodies, methods for production thereof and methods of treatment
#2008Stable multispecific antibodies
#2009Anti-CD3 antibodies and methods of use
#2010Anti-CD3 antibodies and methods of use
#2011ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#2012Bifunctional proteins combining checkpoint blockade for targeted therapy
#2013Antibodies to TIGIT
#2014COMPOSITIONS AND METHODS FOR TREATING CANCER
#2015COMPOSITIONS AND METHODS FOR TREATING CANCER
#2016COMPOSITIONS AND METHODS FOR TREATING CANCER
#2017COMPOSITIONS AND METHODS FOR TREATING CANCER
#2018COMPOSITIONS AND METHODS FOR TREATING CANCER
#2019Compositions and methods for treating cancer
#2020Compositions and methods for treating cancer
#2021Compositions and methods for treating cancer
#2022Compositions and methods for treating cancer
#2023Compositions and methods for treating cancer
#2024Compositions and methods for treating cancer
#2025Methods of treating cancer
#2026Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor
#2027Compositions comprising PKM2 modulators and methods of treatment using the same
#2028Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
#2029Cell secreted minibodies and uses thereof
#2030Treatment of cancer with anti-GITR agonist antibodies
#2031Anti-PD-L1 antibodies and methods of using the same for detection of PD-L1
#2032Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors
#2033COMPOUNDS AND METHODS FOR TUMOUR-SPECIFIC CELL DEPLETION
#2034Antibodies targeting PDL1 and methods of use thereof
#2035Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
#2036Bicyclic compounds and their use in the treatment of cancer
#2037Antibody-drug conjugate
#2038Humanized antibodies against CEACAM1
#2039Trispecific antagonists
#2040PD-L1-specific antibodies and methods of using the same
#2041PHARMACEUTICAL COMPOSITION COMBINING IMMUNOLOGIC AND CHEMOTHERAPEUTIC METHOD FOR THE TREATMENT OF CANCER
#2042COMPOSITIONS AND METHODS FOR TREATING CANCER
#2043PD-L1 and OX40 binding proteins for cancer Regulation
#2044Anti-PD-L1 antibodies and diagnostic uses thereof
#2045Bispecific antibodies with specific binding to CD47 and PD-L1
#2046COMPOSITIONS AND METHODS FOR TREATING CANCER
#2047Compositions and methods for treating cancer
#2048COMPOSITIONS AND METHODS FOR TREATING CANCER
#2049Compositions and methods for treating cancer
#2050Compositions and methods for treating cancer
#2051Compositions and methods for treating cancer
#2052Compositions and methods for treating cancer
#2053USE OF PD-1 AND TIM-3 AS A MEASURE FOR CD8+ CELLS IN PREDICTING AND TREATING RENAL CELL CARCINOMA
#2054Multispecific binding proteins with mutant fab domains
#2055Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis
#2056Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy
#2057Melanin antibodies and uses thereof
#2058Multimeric IL-15-based molecules
#2059SPHERICAL NUCLEIC ACID TLR9 AGONISTS
#2060Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
#2061Anti-TREM1 antibodies and related methods
#2062B7-H4 antibodies and methods of use thereof
#2063Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
#2064COMBINATION THERAPY
#2065BREAST CANCER DETECTION USING B7-H3-TARGETED MOLECULAR IMAGING
#2066Agents modulating beta-catenin functions and methods thereof
#2067TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER (PINK) CELLS IN COMBINATION WITH AN ANTIBODY
#2068Systems and methods for miniaturized antenna for wireless power transmissions
#2069METHOD FOR MEASURING OCCUPANCY RATE OF SPECIFIC BINDING SUBSTANCES IN CELL POPULATION
#2070ANTIBODIES AGAINST PD-L1
#2071ANTI IGF, ANTI PD-1, ANTI-CANCER COMBINATION THERAPY
#2072HaNK cetuximab combinations and methods
#2073Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody
#2074Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
#2075Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
#2076Anti-OX40 antibodies and uses thereof
#2077Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
#2078HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
#2079Antagonists targeting the TGF-β pathway
#2080Biodegradable biomimetic particles
#2081METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
#2082PARP-1 and methods of use thereof
#2083COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS
#2084DOSAGE REGIMENS FOR ANTI-TIM-3 ANTIBODIES AND USES THEREOF
#2085Use of anti-FAM19A5 antibodies for treating cancers
#2086Recombinant vaccinia virus and methods of use thereof
#2087Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#2088Polynucleotides encoding humanized antibodies against CEACAM1
#2089PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1
#2090DOSAGE REGIMEN FOR COMBINATION THERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
#2091Recombinant bispecific antibodies to PD-L1 and CTLA-4
#2092Checkpoint inhibitor and a whole cell for use in cancer therapy
#2093Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
#2094Checkpoint inhibitor and a whole cell for use in cancer therapy
#2095Engineered immunostimulatory bacterial strains and uses thereof
#2096Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus
#2097Methods of classifying response to immunotherapy for cancer
#2098Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
#2099Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibody
#2100Multi-chain polypeptide-containing tri-specific binding molecules